Proteome Sciences plc – LSE:PRM.L

Proteome Sciences stock price today

GBP 5.125
+1.70
+49.85%
Financial Health
0
1
2
3
4
5
6
7
8
9

Proteome Sciences stock price monthly change

-6.56%
month

Proteome Sciences stock price quarterly change

-6.56%
quarter

Proteome Sciences stock price yearly change

-31.19%
year

Proteome Sciences key metrics

Market Cap
9.88M
Enterprise value
1.31B
P/E
4.51
EV/Sales
310.06
EV/EBITDA
229407.18
Price/Sales
3.12
Price/Book
-5.23
PEG ratio
-0.05
EPS
19.39
Revenue
47.23B
EBITDA
-4.50B
Income
9.29B
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-5.09%
Oper. margin
-2.78%
Gross margin
63.06%
EBIT margin
-2.78%
EBITDA margin
-9.54%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Proteome Sciences stock price history

Proteome Sciences stock forecast

Proteome Sciences financial statements

Proteome Sciences plc (LSE:PRM.L): Profit margin
Jun 2022 12.86B 2.47B 19.24%
Dec 2022 10.87B 2.54B 23.43%
Jun 2023 12.62B 3.11B 24.64%
Dec 2023 10.87B 1.16B 10.7%
Proteome Sciences plc (LSE:PRM.L): Debt to assets
Jun 2022 10966000 13.51M 123.2%
Dec 2022 12433000 13.27M 106.78%
Jun 2023 1549714000000 471.90B 30.45%
Dec 2023 1477487000000 1.40T 95.14%
Proteome Sciences plc (LSE:PRM.L): Cash Flow
Jun 2022 13.01B -14.93B 43.73B
Dec 2022 -9.13B -6.73B -16.69B
Jun 2023 14.99B -14.78B 8.72B
Dec 2023 -8.96B -8.63B -17.07B

Proteome Sciences alternative data

Proteome Sciences plc (LSE:PRM.L): Employee count
Aug 2023 27
Sep 2023 27
Oct 2023 27
Nov 2023 29
Dec 2023 29
Jan 2024 29
Feb 2024 29
Mar 2024 29
Apr 2024 29
May 2024 35
Jun 2024 35
Jul 2024 35

Proteome Sciences other data

Insider Compensation
Dr. Mariola Söhngen (1961) Chief Executive Officer & Executive Director
$251,910
Mr. Richard Paul Dennis (1959) Chief Commercial Officer & Executive Director
$184,000
  • What's the price of Proteome Sciences stock today?

    One share of Proteome Sciences stock can currently be purchased for approximately $5.13.

  • When is Proteome Sciences's next earnings date?

    Unfortunately, Proteome Sciences's (PRM.L) next earnings date is currently unknown.

  • Does Proteome Sciences pay dividends?

    No, Proteome Sciences does not pay dividends.

  • How much money does Proteome Sciences make?

    Proteome Sciences has a market capitalization of 9.88M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.98% to 5.03M US dollars.

  • What is Proteome Sciences's stock symbol?

    Proteome Sciences plc is traded on the LSE under the ticker symbol "PRM.L".

  • What is Proteome Sciences's primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of Proteome Sciences?

    Shares of Proteome Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Proteome Sciences's key executives?

    Proteome Sciences's management team includes the following people:

    • Dr. Mariola Söhngen Chief Executive Officer & Executive Director(age: 64, pay: $251,910)
    • Mr. Richard Paul Dennis Chief Commercial Officer & Executive Director(age: 66, pay: $184,000)
  • How many employees does Proteome Sciences have?

    As Jul 2024, Proteome Sciences employs 35 workers, which is 21% more then previous quarter.

  • When Proteome Sciences went public?

    Proteome Sciences plc is publicly traded company for more then 29 years since IPO on 3 Oct 1995.

  • What is Proteome Sciences's official website?

    The official website for Proteome Sciences is proteomics.com.

  • How can i contact Proteome Sciences?

    Proteome Sciences can be reached via phone at +44 20 7043 2116.

Proteome Sciences company profile:

Proteome Sciences plc

proteomics.com
Exchange:

LSE

Full time employees:

35

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Coveham House
Cobham, KT11 3EP

:
ISIN: GB0003104196
CUSIP: G2994J105